Wyeth 1Q Revenues: $5.7 billion (+6%) 1Q Earnings: $1.2 billion (-5%) Comments: Pharmaceutical sales were $4.8 billion (+6%). Growth in the quarter was driven products, Enbrel, Prevnar and Nutritionals, offset, in part, by lower sales of the Protonix family of products due to generic competition. Effexor sales were $1.0 billion (+15%); Prevnar sales were $706 million (+14%); Enbrel sales outside the U.S. and Canada were $606 million (+36%). Alliance revenue was up 21% to $369.0 million...